title: Topical and intratumoral photodynamic therapy with 5-aminolevulinic acid in a subcutaneous murine mammary adenocarcinoma.
abstract: One of the most promising substances used in photodynamic therapy (PDT) is 5-aminolevulinic acid (ALA), which induces endogenous synthesis and accumulation of porphyrins in malignant cells. In this paper we have shown that both topical and intratumoral administration of ALA in a subcutaneously implanted mammary carcinoma produced a significant synthesis of porphyrins and subsequent sensitization to laser light. Porphyrin accumulation was greater when ALA was administered intratumorally and tumour/normal skin porphyrin concentration ratios were higher compared with topical application. Irradiation was optimal between 2 and 3 h after topical application of 50 mg of a 20% ALA cream and 2-4 h after intratumoral administration of 30 mg ALA/cm3. The pattern of tumour response evaluated as the delay of tumour growth was similar following either route of drug administration. Applications of PDT were performed once, twice or three times in the study. The response to successive applications was constant for the same tumour, indicating that no resistance was acquired. Microscopic analysis showed both induction of foci of necrosis and haemorrhage, morphological features of apoptotic cells and total absence of cellular immune response. This paper reports on PDT with topical ALA in a subcutaneous carcinoma leading to tumour growth delay. These findings may have great relevance in the treatment of cutaneous metastasis of mammary carcinomas.
authors.affiliation: Centro de Investigaciones sobre Porfirinas y Porfirias, FCEyN (University of Buenos Aires), Capital Federal, Argentina.
authors.forename: A
authors.initials: A
authors.lastname: Casas
authors.forename: H
authors.initials: H
authors.lastname: Fukuda
authors.forename: R
authors.initials: R
authors.lastname: Meiss
authors.forename: A M
authors.initials: AM
authors.lastname: Batlle
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D000287:Administration, Topical; D000622:Aminolevulinic Acid / Q000008:administration & dosage*; D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects; D015552:Injections, Intralesional; D007834:Lasers; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000096:biosynthesis; D012867:Skin / Q000378:metabolism; D012878:Skin Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D013997:Time Factors
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000622:Aminolevulinic Acid